Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

TA Associates – the highly respected growth-oriented, private equity software investor – has acquired secure edge OS powerhouse IGEL and added former Microsoft software superstar Bill Veghte ...

HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment ...

The company’s founders, management team, and existing investors, which include Springcoast, GV, Polaris, and Kleiner Perkins, will retain significant ownership in Egnyte.

Egnyte provides businesses with cloud-based content intelligence, governance, and collaboration tools through a unified intelligent content platform. The company’s solutions integrate AI, file storage ...

The deal, the terms of which have not been disclosed, will give Novo Holdings and TA Associates, shared control of the UK-based manufacturer of products for infection management in bone and soft ...